Ask AI
ProCE Banner Activity

Beamion LUNG-1: Phase Ib Study of Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases

Conference Coverage
Slideset

A pooled analysis of the phase Ib Beamion LUNG-1 study showed promising intracranial response rates with zongertinib in patients with advanced, HER2-mutant, NSCLC with stable, asymptomatic or active brain metastases at baseline.

Released: November 13, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.